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Non-coding RNANeuroblastoma Differentiation Marker 29 (NDM29) is a RNA polymerase (pol) III-transcribed non-coding
(nc) RNA whose synthesis drives neuroblastoma (NB) cell differentiation to a nonmalignant neuron-like phe-
notype. Since in this process a complex pattern of molecular changes is associated to plasma membrane pro-
tein repertoire we hypothesized that the expression of NDM29 might inﬂuence also key players of
neurodegenerative pathways. In this work we show that the NDM29-dependent cell maturation induces am-
yloid precursor protein (APP) synthesis, leading to the increase of amyloid β peptide (Aβ) secretion and the
concomitant increment of Aβ x-42/Aβ x-40 ratio. We also demonstrate that the expression of NDM29 RNA,
and the consequent increase of Aβ formation, can be promoted by inﬂammatory stimuli (and repressed by
anti-inﬂammatory drugs). Moreover, NDM29 expression was detected in normal human brains although
an abnormal increased synthesis of this ncRNA is induced in patients affected by neurodegenerative diseases.
Therefore, the complex of events triggered by NDM29 expression induces a condition that favors the forma-
tion of Aβ peptides in the extracellular space, as it may occur in Alzheimer's Disease (AD). In addition, these
data unexpectedly show that a pol III-dependent small RNA can act as key regulator of brain physiology and/
or pathology suggesting that a better knowledge of this portion of the human transcriptome might provide
hints for neurodegeneration studies.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Soluble and insoluble aggregates of Aβ or intracellular tangles of
hyperphosphorylated Tau protein have been alternatively regarded
as the most likely causes of neurodegeneration in AD (reviewed in
[1,2]). In particular, the “amyloid hypothesis” originates by the obser-
vation that post mortem analysis of AD patients' cerebral cortices rev-
ealed amyloid plaques within the brain parenchyma [3]. This
phenomenon is mainly due to an increased secretion of Aβ (the
main component of amyloid plaques) in the extracellular space. In
particular, an enhanced ratio between the two Aβ molecular variants
(Aβ x-42 and Aβ x-40), favoring the formation of the less soluble Aβ
x-42 variant, was observed. As a consequence, high amounts of a mix-
ture of neurotoxic Aβ peptides accumulate in the brain. However, al-
though increasing body of evidence supports a primary role of Aβ in
the etiology of AD, little is known about the upstream events that+39 010 5737257.
l rights reserved.trigger the amyloid cascade, so that the ﬁrst disease-causing events
still remain unknown. In this context several research approaches
have been developed to investigate different possible pathogenetic
events for AD. Among these, prolonged inﬂammatory stimuli are
thought to be part of the complex pattern of events that ultimately
lead to the onset of the disease-associated conditions, such as in-
creased secretion and aggregation of Aβ peptides synaptic dysfunc-
tion, reactive gliosis and the generation of neuroﬁbrillary tangles of
hyperphosphorylated Tau [4–9].
Besides this working hypothesis, emerging evidence supports the
possibility of incomplete, defective attempt to cell cycle re-entry as a
possible cause of neuron death in AD [10,11]. In this view aberrant
mitotic stimuli might be generated in neurons of AD patients and,
as a consequence lead post-mitotic neurons to apoptosis [12]. This
hypothesis is currently supported by experimental observations,
showing an association between high aneuploidy rate, chromosomal
missegregation and AD [13]. Interestingly, a link between the control
of cell cycle and AD has been also recently proposed by epidemiolog-
ical observations. Indeed, a diminished risk of AD in cancer patients
and a highly reduced risk of cancer associated to AD have been docu-
mented [14].
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Marker 29 (NDM29), a RNA pol III-transcribed ncRNA whose synthe-
sis is lead by an extragenic type 3 promoter composed by a TATA box,
a Proximal Sequence Element (PSE) and a Distal Sequence Element
(DSE) [15]. A preliminary expression analysis showed that NDM29
is actively transcribed in cells of the central nervous system, whereas
cells characterized by epithelial-like phenotype synthesize a modest
amount of this ncRNA. In order to investigate the functions of
NDM29 we generated two genetically engineered SKNBE2 neuroblas-
toma (NB) cell lines that overexpress NDM29 [16,17]. Interestingly,
we found a direct relationship between the expression levels of this
ncRNA and cell differentiation toward a neuron-like phenotype. In-
deed, the expression of NDM29 strongly restricts the malignant po-
tential of NB cells leading to their maturation to a non-malignant
neuron-like phenotype [16,17]. In particular, we demonstrated that
NDM29 overexpression caused neuronal differentiation of S1.1 cells
in terms of molecular markers (high increase in the transcription of
GD2 synthase and NF68, while modest increase in glial markers)
and electrophysiological behavior (we detected high levels of fast
inactivating Na+ current, able to generate mature action potentials
and induction of the expression of functional GABA-A receptors on
their membrane) [17]. These indicators show that NDM29 expression
in S1.1 cells is accompanied by a well-coordinated differentiation pro-
cess toward the neuron-like phenotype [17].
In this context, the aim of this study was to evaluate whether the
expression of NDM29 might also inﬂuence the processing of APP and/
or the amyloid cascade whose perturbation is involved in AD
development.
We show that a sustained overexpression of NDM29 actively pro-
motes the molecular processing and the secretion of Aβ peptides,
thus inﬂuencing the main secretory pathway thought to be involved
in AD development. High level of transcription of NDM29 increases
APP synthesis and leading to the increase of Aβ secretion. Notably,
the increase in Aβ production is mainly ascribed to the toxic insoluble
form Aβ x-42, considered of primary relevance for AD etiology [18].
Finally, we demonstrate that the synthesis of NDM29 RNA can be pro-
moted by inﬂammatory stimuli (and repressed by antiinﬂammatory
drugs) and that this ncRNA, actually detected in human brains, is ab-
normally expressed in AD patient brains.
2. Materials and methods
2.1. Cell culture and transfection
Different cell lines were used: S1.1, S6, S7, M and M2 cells are
SKNBE2 neuroblastoma cells (provided by the cell bank of the Nation-
al Institute of Cancer Research (IST) Genoa, Italy and obtained from
ECACC, [19]) stably transfected with pNDM29-EGFPN1 or pEGFPN1
empty vector respectively as described in [20] (both grown in RPMI
supplemented with 10% FBS, 1% glutamine and 200 μg/mL G418)
and transiently transfected with pNDM29-EGFPN1, pAntiNDM29-
EGFPN1 (pS1.1/A) and pEGFPN1 (grown in DMEM supplemented
with 10% FBS, 1% glutamine). HEK293-APP cells were a kind gift of
Prof. Luciano D'Adamio (Albert Einstein College of Medicine, NY,
USA). Cells were transfected using PEI (polyethylenimine) (SIGMA
P3143).
2.2. Real time quantitative RT-PCR analysis
Total RNAs from samples were extracted using TRIzol reagent
(Invitrogen) according to the manufacturer's protocol, DNAseI-
digested and subjected to reverse transcription by Transcriptor
High Fidelity cDNA Synthesis Kit (Roche 05081955001) as described
in [21]. The total RNA from the samples was measured by real-
time quantitative RT-PCR using Power SYBR Green PCR Master
Mix (Applied Biosystems) following manufacturer's instructions.The sequences of forward and reverse primers were: c-kit: 5′-
GCAAGTCAGTGCTGTCGGAA and 5′-AAGATAGCTTGCTTTGGACACA-
GA-3′; mmp-9: 5′-CACTCGCGTGTACAGCCG-3′ and 5′-TCGAAG-
GGATACCCGTCTCC-3′; NF-68: 5′-CAAGGACGAGGTGTCCGAG-3′ and
5′-CCCGGCATGCTTCGA-3′; APP: 5′-TGGCCCTGGAGAACTACATCA3′
and 5′-CGCGGACATACTTCTTTAGCATATT-3′; NDM29: 5′-GGCAGG-
CGGGTTCGTT-3′ and 5′-CCACGCCTGGCTAAGTTTTG-3′. For endogenous
control the expression of Glyceraldehyde 3 phosphate dehydrogenase
(G3PDH) gene was examined. The sequences for human G3PDH
primers were 5′-GAAGGTGAAGGTCGGAGTC-3′ and 5′- GAAGATGG-
TGATGGGATTTC-3′. Relative transcript levels were determined from
the relative standard curve constructed from stock cDNA dilutions,
and divided by the target quantity of the calibrator following man-
ufacturer's instructions.
2.3. Immunoﬂuorescence detection
S1.1 and Mock SKNBE2 cells grown on slides, were ﬁxed with
methanol, washed 3 times with PBS and incubated with the different
primary antibodies in PBS plus 1% NGS for 1 h, and ﬁnally incubated
with antigen-speciﬁc secondary antibodies (Alexa 488 or 568-
conjugated, and AMCA from Invitrogen Corporation, Carlsbad, CA,
USA). Cells were then mounted by Mowiol and analyzed on BioRad-
MRC 1024 ES confocal microscope, equipped with a Nikon Eclipse
TE 300 inverted microscope with a 60× objective lens as reported
in [22]. Antibody for mouse GM130 (BD USA) was used at the dilution
1:100, mouse α-tubulin (Sigma) 1:1000 and Rabbit N-terminal APP
(Sigma) 1:100; Alexa Fluor® 568 and Alexa Fluor® 488 (Molecular
Probes, Invitrogen Corporation, Carlsbad, CA, USA) were used 1:200.
2.4. ELISA Aβ detection
The amount of secreted Aβ x-40 and Aβ x-42 were evaluated by
Human Amyloid (1–40) Assay Kit (IBL 27713) and Human Amyloid
(1–42) Assay Kit (IBL 27711) according to the manufacturer's
protocol.
2.5. Western blots
Proteins were quantiﬁed using a commercial protein quantiﬁca-
tion kit (Protein Assay, Bio-Rad 500–0006) as described in [23]. The
samples were subsequently analyzed by 10% SDS PolyAcrylamide
Gel Electrophoresis (SDS–PAGE) and transferred to a nitrocellulose
membrane (Whatman, Inc.). The membranes were initially blocked
by an incubation of 2 h in Tris-buffered saline Tween 20 (TBST;
50 mM Tris–HCl, 150 mM NaCl, pH 7.5, 0.05% Tween 20) containing
5% non-fat dried milk. The blots were incubated for 1 h with the ap-
propriate primary antibodies: rabbit polyclonal anti-APP c-terminal
(A 8717 Sigma) (1:1000); rabbit polyclonal anti-Presenilin1 (S182
Sigma) (1:2000); rabbit polyclonal anti-Presenilin2 (sc-7861 Santa Cruz
Biotechnology) (1:200); rabbit polyclonal antibody anti-BACE1 (pc529,
Calbiochem) (1:300). After washing with TBST membranes were incu-
bated with peroxidase-conjugated secondary antibodies [anti-rabbit
IgGs (A 0545, Sigma)(1:16000)] for 1 h at room temperature. After
washing the reactive bands were revealed with ECL Plus Western Blot-
ting Detection Reagents (Amersham RPN2132). In order to normalize
the protein levels, western blot membranes were stripped with “Re-
store” (Pierce 21059), a western blot stripping reagent, then probed
with a monoclonal antibody against-α-tubulin (T 5168 Sigma)
(1:2000). Amyloid C-Terminal Fragmentwestern blot analysis was per-
formed by running protein samples on 14% Tris-Tricine gel. The mem-
branes were blocked by an incubation of 1 h in Phosphate-buffered
saline Tween 20 containing 5% non-fat driedmilk. The blotwas incubat-
ed overnight with the primary antibody, rabbit polyclonal anti-APP, c-
terminal (A 8717 Sigma) (1:1000), diluted in 0.1% NaN3 in PBS. The
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tage of ImageJ software system.
2.6. Human brain samples
Frontal and temporal cortices from AD (diagnosis was made after
evaluating clinical history of disease and pathological diagnosis
according to the Consortium to Establish a Registry for Alzheimer's
Disease (CERAD) criteria) and control cases (AD excluded by clinical
history and by immunohistochemical analysis) derive from: the
Brain Bank at Case Western Reserve University, Cleveland, OH, and
the Joseph and Kathleen Bryan Alzheimer's Disease Research Center
(Bryan ADRC) at Duke University Medical Center, Durham, NC.
Small pieces (50–100 mg) of gray matter from frontal and temporal
cortices were excised under sterile conditions; tissue RNA and pro-
teins were extracted following standard procedures.
The frozen brain samples collected at the Brain Bank indicated in
Section 3.5 were collected in different years under the approval of
the local ethics committees for the routine activity proper of the
Brain Bank. The agreements between Brain Banks and Universities
normally only require that the research activities with these tissues
will be conducted within the aim of non proﬁt scientiﬁc research. In
fact the speciﬁc agreement between the Brain Banks and CR states
that the research should be made under non proﬁt conditions and
that the Bank will be acknowledged (see Section 3.5).
2.7. Pro- and anti-inﬂammatory stimuli
Cells treated with TNF-α (tumor necrosis factorα), LPS (bacterial li-
popolysaccharides) and IL-1α (pro-inﬂammatory stimuli) or diclofenac
20 μM (anti-inﬂammatory stimuli) for 16 h were processed for the ex-
traction of RNA to be analyzed by RT-PCR as described in Section 2.2
while the conditioned media were collected for Aβ x-40 and Aβ x-42
detection.
3. Results
3.1. NDM29 RNA expression leads to the neuron-like differentiation of
SKNBE neuroblastoma cells
We recently challenged the human genome in order to identify
novel RNA pol III transcription units [15]. We found that one tran-
scription unit of the newly obtained collection maps in 11p15.3,
in the ﬁrst intron of the Achaete Scute-Like 3 gene (Acc. No.
AJ400877), an Helix-Loop-Helix transcription factor involved in the
development of the nervous system in drosophila [24]. Since its syn-
thesis was increased in the advanced stages of NB cell maturation we
named this small RNA (NDM29) [16]. In previous studies on NDM29
function, we showed that its overexpression confers a neuron-like
phenotype to NB cells, including membrane ion currents usually ob-
served in cells endowed with functional synapses [17]. Interestingly,
the synthesis of NDM29 strongly restricts NB malignant potential
and makes cells susceptible to the action of some antiblastic drugs
inhibiting the synthesis of the multidrug resistant (MDR) 1 detoxiﬁ-
cation pump [16].
In order to investigate in detail the function of NDM29, we generat-
ed aNDM29-overexpressing cell line by the permanent transfection of a
pNDM29-EGFPN1 plasmid [harboring NDM29 transcriptional unit driv-
en by its endogenous promoter and a Green Fluorescent Protein (GFP)
cassette] in SKNBE2 NB cells. After selection for antibiotic resistance,
we observed that cells that integrated extra copies of NDM29 transcrip-
tion unit exhibit a population doubling time (PD) of 48 h (whereas their
Mock counterpart have a PDof 30 h) and are characterized by a dramat-
ic reduction of the malignant potential. A subclone of this cell popula-
tion (hereafter referred to as S1.1) was further characterized for its
differentiation potential. As shown in Fig. 1A, S1.1 cells show a markedneuron-like phenotype characterized by a big cell body and well orga-
nized neuritic processes. Real time RT-PCR analysis of these cells
evidenced a 2.5-fold increased expression of NF68 [Neuroﬁlament 68,
a protein speciﬁc of neuroﬁlaments (NP_006149.2)] (Fig. 1B), while a
3.9-fold increase of positivity to HuD [Hu-antigen D, a neuron-speciﬁc
marker (NP_001138246.1)]was demonstrated by immunoﬂuorescence
detection (Fig. 1C). In these experiments the neuron-like maturation
stage of S1.1 and Mock cells was assessed by measuring with Real
Time RT-PCR the expression of neuron-speciﬁc molecular markers
such as MMP9 [Matrix Metalloprotease 9], a marker of differentiation
toward neuron (NP_004985.2) [25], c-Kit [a marker of stemness highly
expressed by undifferentiated neuroblastoma cells (NP_000213.1)]
and NDM29 RNA. Results, normalized to Mock controls, show 8.4-
fold and 5.8-fold increased expression of NDM29 and MMP9, respec-
tively, in S1.1 cells as expected in a well-differentiated stage of matu-
ration. Accordingly, in these cells the synthesis of c-Kit is strongly
inhibited, corroborating the commitment toward a neuron-like differ-
entiation acquired by S1.1 cells (see Supporting Information File Figure
S1). Altogether with previous experiments described elsewhere [16],
these results demonstrate that the phenotype of S1.1 NB cells recalls
that of neuron-like cell and might represent a useful in vitro model
to assess the role of NDM29 in neurological syndromes.
3.2. The expression of NDM29 promotes Aβ secretion from SKNBE2
neuroblastoma cells
New emerging evidences suggesting that ncRNAs mediate several
brain regulatory events [26-28] along with the observation that
NDM29 actively leads NB cells to a neuron-like differentiated stage,
allowed us to postulate the possible involvement of this ncRNA in
the physiology and/or pathology of neurons. To test this hypothesis,
we investigated the possible correlation between the expression of
NDM29 and Aβ formation. To this aim we measured using ELISA the
amount of Aβ x-40 and Aβ x-42 in the cell culture medium condi-
tioned for 2 days by Mock (M) or S1.1 cells. Results show that the
concentration of total Aβ formed by S1.1 cells was increased up to
1179 pg/l with respect to the original level of Mock control
(758.6 pg/l) (Fig. 2A). Indeed, in S1.1 cells, harboring extra copies of
NDM29 transcription unit, we observed 1.5- and 2.0-fold increases
in the amount of Aβ x-40 and Aβ x-42, respectively, as compared to
Mock control cells. Next, to assess a direct correlation between
NDM29 synthesis with Aβ secretion we re-overexpressed NDM29
RNA (transfecting transiently NDM29 plasmid in S1.1 cells) and/or
we restored the basal level of NDM29 expression (transfecting a plas-
mid encoding antiNDM29, a microRNA directed against NDM29 RNA
able to decrease its amount in the cell) and measured the correspon-
dent amount of Aβ secreted. As expected, we found a signiﬁcant in-
crease of both Aβ x-40 and Aβ x-42 in S1.1 cells transiently
transfected with NDM29 plasmid whereas downregulation of this
phenomenon was observed in cells transfected with Anti-NDM29
construct (Fig. 2B,C).
Therefore, NDM29 synthesis provokes a general increase of the
total amyloid secreted and an enhanced Aβ x-42 vs Aβ x-40 ratio.
3.3. NDM29 expression promotes the amyloidogenic processing of the
amyloid precursor protein
To gain insights into the molecular mechanism by which
NDM29 triggers Aβ secretion, we evaluated the possible modula-
tion of the synthesis of key proteins involved in Aβ formation
induced by this ncRNA. To this aim we measured the expression
of APP (Amyloid Precursor Protein), PS1 (Presenilin 1, Acc. No.
NP_000014.8), PS2 (Presenilin 2, Acc. No. NC_000001.10) and
BACE (Beta Site APP Cleaving Enzyme, Acc. No. NC_000011.9) in
S1.1 and Mock cells. The results obtained demonstrate that in S1.1
cells the synthesis of APP is 3.0- and 3.4-fold increased at mRNA
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Fig. 1. Differentiated phenotype of NDM29-overexpressing cells. A. Mock (left panel, M) and S1.1 (right panel) cells. B. Real Time RT-PCR analysis of NF68 expression; results are
normalized to M cells (p=0.0007). C. Increased positivity to HuD antigen in S1.1 (right panel) with respect to Mock (left panel) cells. The quantitative determination is reported as
resulting by the averaged percentage of positive cells in 10 randomly chosen microscope ﬁelds (p=0.0001).
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this ﬁnding we measured the amount of NDM29 RNA and APP
(mRNA and protein) in Mock, S1.1 and S1.1 transfected with a plas-
mid encoding antiNDM29. As expected, the results showed that
also in transient conditions the up- and down-regulation of
NDM29 RNA is accompanied by the correspondent modulation of
APP synthesis (Fig. 3A′). Last, we excluded that the observed effects
were due to clonal selection of the NDM29 expressing cells, mea-
suring the amount of NDM29 and APP (protein and mRNA) in
three additional S1.1 cell lines (a novel Mock and two independent
NDM29-overexpressing clones) evidencing that also in different cell
clones the upregulation of NDM29 RNA drives the increase of APP
synthesis (Fig.3A″).A B
C
Fig. 2. Aβ secretion. A. Average of three independent determinations of Aβ secretion by
M- and S1.1-conditioned media as a result of using Elisa assay (S.D. is not detectable)
(Aβ TOT P=0.0004; Aβ40 P=0.0005 Aβ42 P=0.0006; ratio Aβ 42/Aβ x40 P=0.0006). B,C. Aβ x40
(B) and Aβ x42 (B) determinations in media conditioned by S1.1 cell re-transfected
transiently with pNDM29 (S1.1) or pAnti-NDM29 (pS1.1/A) plasmids.In the same cells, BACE protein level is unaltered (Fig. 3B). Similarly,
the expression of PS1 and PS2 modulations of protein expression, as
well as of their N-terminal fragments, is only barely detectable and
statistically not signiﬁcant (Fig. 3C,D). These data indicate that the
NDM29-dependent induction of APP synthesis might play a role in the
increase of Aβ secretion with a mechanism that does not involve the
up-regulation of the components of the β- (BACE) or γ-secretase (PS1
and PS2) complexes (Fig. 3A–D).
In order to assess the speciﬁcity of the effects elicited by NDM29
on APP synthesis, we veriﬁed, by Western blotting, the expression
of two unrelated neuronal proteins involved in neurodegenerative
disorders, prion protein (PrP) and calsenilin (potassium channel
interacting protein 3 or KChIP3). PrP is a small glycoprotein responsi-
ble of transmissible spongiform encephalopathies such as scrapie and
bovine spongiform encephalopathy in animals and Kuru, Creutzfeldt-
Jacob disease, Gerstmann–Straussler syndrome and fatal familial in-
somnia in humans [29]. Calsenilin is a neuronal calcium-binding pro-
tein, that has been shown to have multiple functions including the
regulation of calcium signaling, cell death presenilin processing, re-
pression of transcription and modulation of A-type potassium chan-
nels [30].
No signiﬁcant differences in the expression of these two proteins
in the S1.1 with respect to M cells were observed (Fig. 3E), supporting
the notion that the NDM29-dependent effects here documented are
associated to the overexpression of this ncRNA and not to a general/
aspeciﬁc increase of protein synthesis.
To verify whether the increase in Aβ secretion was the resultant of
alterations in APP subcellular localization, we analyzed changes in
APP intracellular localization in S1.1 and Mock cells, by confocal mi-
croscopy. Speciﬁc primary antibodies were used to label APP at the
N-terminal domain followed by secondary antibodies carrying
ﬂuorophores (Alexa 568). First, we quantiﬁed the ﬂuorescence inten-
sity induced by APP immunolabeling (measured by Laserpix software,
Bio-Rad Microscience Ltd) showing a 2.45 fold increased signal of APP
in S1.1 cells with respect to Mock control, conﬁrming that in NDM29-
overexpressing cells the amount of APP suitable for Aβ processing is
signiﬁcantly enhanced. Next, we tested the possible alterations of
Fig. 3. NDM29-driven increase of APP processing. A–D. APP, BACE, Presenilin 1 and Presenilin 2 expressions increase in M or S1.1 cells either at protein or at mRNA level as a result
by western blotting and Real Time RT-PCR respectively (APP protein p=0.0003, APP RNA p=0.0007; BACE protein p=0.0003). X axis, cell type; Y axis, -fold increase. A′. APP
mRNA, APP protein and NDM29 expressions in Mock, S1.1-transfected and/or S1.1 silenced cells. A″. APP mRNA, APP protein and NDM29 expressions in additional NDM29-
overexpressing cell lines. E. Prion Protein and KChIP3 western blotting quantitation; ERK, protein loading control; quantitative determination of APP ﬂuorescence intensity by con-
focal microscopy in F: Mock and S1.1 cells (p=0.0012). Red (Alexa 568), APP; green (Alexa 488), GM130. F′: Mock, S1.1-transfected (S1.1) (p=0.00052) and/or S1.1-silenced
(S1.1/A) cells (p=0.0051). Red (Alexa 568), APP; green (Alexa 488), α-tubulin. G. C-terminal fragments western blotting analysis in M and S1.1 cells. H. C-terminal fragment west-
ern blotting analysis in M and S1.1 cells in BACE Inhibitor IV-treated and/or untreated HEK293 cells.
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aim we labeled cells with primary antibodies directed against APP
and GM130 (Golgi matrix protein of 130 kDa, a Golgi apparatus asso-
ciated protein), followed by secondary antibody carrying Alexa 568
for APP, and Alexa 488 for GM130. Confocal analysis showed exten-
sive perinuclear, endoplasmic reticulum, and spots of co-localization
between APP and GM130 in Golgi demonstrating that, besides the al-
teration of APP content, no differences in terms of subcellular locali-
zation were detected between S1.1 and Mock cells (Fig. 3F). In
summary, confocal analysis showed an equivalent APP subcellular lo-
calization between S1.1 and Mock cells but a signiﬁcant increase of
APP immunolabeling in S1.1 cells, thus conﬁrming that NDM29 pro-
motes Aβ formation increasing the amount of APP suitable for pro-
cessing. Next, in order to strengthen the above result we repeated
the same ﬂuorescent determinations in an experimental setting of
transient up-/down-regulation of NDM29 synthesis. Again, results
showed that the expression level of APP is directly related to the syn-
thesis of NDM29 RNA corroborating further the results obtained pre-
viously (Fig. 3F′).
Then, we investigated whether NDM29-dependent increased se-
cretion of Aβ is only caused by augmented APP synthesis or is also fa-
vored by enhanced cleavage by β- and/or γ-secretase complexes.
Notably, we observe a strong increase of APP C-terminal fragments
detected in S1.1 cells by SDS PAGE/immunoblotting analysis,
suggesting that the expression of NDM29 speciﬁcally promotes the
increase of BACE cleavage (Fig. 3G). To clarify whether the increaseof CTFs observed in NDM29-overexpressing cells was due to an en-
hanced cleavage by β-secretase, we took advantage of a BACE-
speciﬁc inhibitor (565788 β-Secretase Inhibitor IV, Calbiochem)
[31]. To overcome the low production of CTFs of wt NB cells during
the limited time of treatment, we incubated overnight HEK293 cells
with 5nM β-Secretase Inhibitor IV followed by a transfection with
pNDM29- (NDM) or pMock- (M) plasmid construct. As shown in
Fig. 3H, in the presence of the BACE inhibitor, the increase in C-
terminal fragments produced by untreated pNDM29-transfected cells
was abolished. This indicates that, as hypothesized, the increase of
CTFs is a consequence of an increased cleavage activity of BACE.
Altogether the above experiments demonstrate that the over-
expression of NDM29 ncRNA leads to an increased cleavage of APP
by β-secretase. Therefore, NDM29 ncRNA expression promotes Aβ se-
cretion via a complex mechanism that involves the increased synthe-
sis of Aβ precursor and the improvement of its processing by BACE
that, in turn, generates an enhanced amount of APP C-terminal frag-
ments suitable for further processing by the γ-secretase cleavage
complex.
3.4. NDM29 expression is triggered by inﬂammatory stimuli
Because the above ﬁndings suggest a possible role of NDM29 in
AD, we focused the investigation on the mechanisms regulating the
pol III-dependent synthesis of NDM29 in neurodegenerative disor-
ders. In light of the several reports supporting the hypothesis of a
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we tested the effect of a widely used pro-inﬂammatory molecule, in-
terleukin 1α (IL-1α) on NDM29 transcription. We found that 12 h
after treatment of SKNBE wt cells with IL-1α (0.5 ng/ml) the expres-
sion of NDM29 is signiﬁcantly increased, whereas in samples
pretreated with diclofenac, a potent non-steroidal antiinﬂammatory
drug, basal transcription of NDM29 is inhibited (Fig. 4A). Interesting-
ly, IL-1α-dependent induction of NDM29 was correlated with a sig-
niﬁcant increase in the formation of total β-amyloid and Aβ x-42/
Aβ x-40 ratio that was exclusively associated with enhanced amount
of the Aβ x-42 molecular species (Fig. 4B). In order to extend the pos-
sible induction of NDM29 synthesis by other inﬂammatory agents we
treated S1.1 cell with different dosages of TNFα (tumor necrosis fac-
tor α) and/or LPS (bacterial lipopolysaccharide) and measured possi-
ble variations of NDM29 RNA synthesis. Results showed that, with the
exception of one dose of LPS (0.5 μg/ml), NDM29 synthesis was in-
duced by the treatment in a dose-dependent manner.
Altogether the above results demonstrate that NDM29 synthesis
(and its detrimental consequences on Aβ formation) can be driven
by inﬂammatory stimuli.
3.5. NDM29 is overexpressed in AD post mortem cerebral cortex samples
Since the overexpression of NDM29 generates a cascade of reac-
tions associated to neurodegenerative conditions, we tested the pos-
sible overexpression of NDM29 in post-mortem cerebral cortices
comparing AD patients and non-diseased control individuals (see
Supporting Information File Table S1) by Real Time RT-PCR. The anal-
ysis of the expression of NDM29 in 10 samples of non-demented in-
dividuals and 13 AD cases showed that the averaged expression
level of the AD samples was 6-fold higher than that of non-diseased
controls (Fig. 5). However, a high individual variability was observed
among diseased and control samples. We thus crossed individual ex-
pression level of NDM29 with different pathological characteristics
available for the patients. We found that, despite on average
NDM29 is unequivocally upregulated in AD cerebral cortices, its ex-
pression is not directly associated to any of the speciﬁc conditions an-
alyzed, thus suggesting that there might be a different factor that is
able to mediate the expression of NDM29 in AD (see Supporting In-
formation File Table S1). In any case, altogether these data suggest
that in vivo NDM29 synthesis occurs in normal human brain and
that it is enhanced in the brains of AD patients, possibly contributing
to increased Aβ secretion.NT
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by IL-1α treatment (AβTOT P=0.002, Aβ42 P=0.002). S1.1 cell treated with different dosage4. Discussion
We recently published the discovery of NDM29, a pol III-transcribed
ncRNA whose synthesis strongly restricts NB development. Indeed, the
increased expression of NDM29 in neuroblastoma cells activates a cas-
cade of molecular changes that, strongly restricts the malignant poten-
tial of NB cells and, leads to the acquisition of a neuron-like phenotype
[16,17].
In this study, we hypothesized that the expression of NDM29
might also inﬂuence the processing of APP and/or the amyloid cas-
cade whose perturbation are involved in AD development.
We demonstrate that the complex reorganization of cell mem-
brane protein repertoire that attends NDM29-dependent differentia-
tion also affects the expression and/or the enzymatic activity of key
players of neurodegenerative pathways. Indeed, a high level of ex-
pression of NDM29 leads to (1) the overexpression of APP, (2) the in-
crease of the β-secretase cleavage, (3) the consequent increase of Aβ
formation and (4) the concomitant increment of Aβ x-42/Aβ x-40
ratio. Altogether, these events generate a condition previously hy-
pothesized to favor the toxic cascade associated to the development
of AD. Therefore, these ﬁndings suggest that the complex pattern of
molecular changes driven by NDM29 overexpression might contrib-
ute actively to the formation of amyloid in the extracellular space fa-
voring neurodegeneration.
Increased APP level is per se sufﬁcient to induce AD phenotype in
familial patients either bearing mutations in the promoter region of
APP [32,33] or extra copies of APP as in Down's syndrome subjects.
In sporadic AD cases it is hypothesized that mosaicism and local de-
fective chromosomal instability might lead to enhanced APP levels
[34,35].
In this paper we provide evidence for a further mechanism by
which APP levels and processing may be modulated, related to the ex-
pression of a novel a non-coding RNA, whose levels of transcription
are upregulated by inﬂammatory stimuli (a schematic description of
the proposed model is reported in Fig. 6). Interestingly, while we
identify in NDM29 overexpressing cells increased β-secretase activi-
ty, the protein content of the main components of the β-secretase
complex, PS1 and PS2, is unchanged. We propose that, the increase
of substrate availability can be translated in higher amount of cleav-
age products (see Fig. 3G).
A further demonstration of the possible role of NDM29 in the reg-
ulation of Aβ secretion in vivo was obtained by the analysis of the ex-
pression of this ncRNA in the cortex of post mortem human brain0 A  42
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1176 S. Massone et al. / Biochimica et Biophysica Acta 1823 (2012) 1170–1177samples. It is important to underline the fact that NDM29 is actually
expressed in the human brain to a basal low level (see data in non-
demented control brains) and that in particular, notwithstanding sig-
niﬁcant inter-individual differences, NDM29 is overexpressed in AD
brains, in comparison to non-AD control samples. At the present
state further experiments are needed to deﬁne the cause of the high
individual variation and possibly its correlation with clinico-
pathological conditions, although we can hypothesize a relationship
with the individual brain inﬂammatory conditions. In any case,
these data suggest that the overexpression of NDM29 might be di-
rectly involved in, or contribute to Aβ production in AD patients, pro-
moting a condition that favors the onset of neurodegenerative
processes. Importantly, the observation that NDM29 expression can
be promoted by inﬂammatory mediators and, possibly, reduced by
non-steroidal antiinﬂammatory drugs keeps in line with the hypoth-
esis of prolonged inﬂammation as one of the possible causes of AD
onset, a view also supported by epidemiological data. As far as IL-
1α regulation of Aβ production is concerned, it is worth to note that
a different pattern of APP fragments was generated (a high increase
in Aβ x42 and no change in Aβ x-40) as compared to S1.1 cells (in
which both fragments were induced although with a higher effectNeuron-like commitment
Inflammatory 
stimulus
NDM29 RNA BACE c
c
APP
Activ
γ-s
Fig. 6. Schematic model of the possible contron Aβ x-42). However, we have to point out that (1) in both condi-
tions we have the same ﬁnal effect (increase of Aβ x-42/Aβx-40
ratio) correlated with high levels of NDM29; (2) the different re-
sponse may reﬂect other IL-1α effects independent of NDM29; (3)
differently from the cells treated with the cytokine, S1.1 cells are sta-
bly expressing NDM29 and thus, in the latter case, some adaptive
mechanisms may be generated that somehow partially modify the
ncRNA activity.
Last, the fact that a regulatory RNA that strongly restricts the ma-
lignant potential of cancer cells can promote amyloidogenesis is par-
ticularly intriguing in the light of recent data evidencing that cancer is
associated to a signiﬁcantly reduced risk of AD whereas AD is accom-
panied by a strongly decreased risk to develop cancer [14,36]. In this
context NDM29 and the modulation of its synthesis might provide a
molecular link between these two pathological manifestations.
In conclusion, the results presented here describe the active role
played by a pol III-transcribed ncRNA in the regulation of amyloid
processing (Fig. 6), providing a novel sight on AD-related processes
and, possibly, its link with tumor malignant potential. In addition,
these data unexpectedly show that a pol III-dependent small RNA
can act as key regulator of brain physiology and/or pathologyleavage
leavage 
activity 
 synthesis C-99 
Aβ 40/Aβ 42 
Amyloidosis
Neuron 
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ratio 
ity 
ecretase 
ibution of NDM29 to amyloid secretion.
1177S. Massone et al. / Biochimica et Biophysica Acta 1823 (2012) 1170–1177suggesting that further investigation of this portion of the human
transcriptome and its expression regulation is needed as it might pro-
vide further hints for neurodegeneration studies.
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